International research led by University College London (UCL) as part of the ‘Cities Changing Diabetes’ partnership programme challenges current scientific understanding of the rapid rise of diabetes in cities. The findings suggest that in cities around the world, social and cultural factors play a far more important role in the spread of the epidemic than previously thought.
More than two thirds of the world’s 400 million people with diabetes live in urban areas.1,2 The year-long study for Cities Changing Diabetes, a unique public-private-academic partnership, sought to better understand what makes people vulnerable to type 2 diabetes in cities in order to inform solutions for one of the most pressing modern-day public health challenges. To explore this complex issue, more than 550 interviews were undertaken with at-risk and diagnosed people in five major cities – Copenhagen, Houston, Mexico City, Shanghai and Tianjin.
“By largely focusing on biomedical risk factors for diabetes, traditional research has not adequately accounted for the impact of social and cultural drivers of disease,” says David Napier, Professor of Medical Anthropology, UCL. “Our pioneering research will enable cities worldwide to help populations adapt to lifestyles that make them less vulnerable to diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7690951-study-rethink-rise-diabetes-in-cities/
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced its next-generation mobile strategy for the laboratory―to provide a flexible and secure mobile computing environment that effectively connects scientists, equipment and materials in today’s laboratories where an increasing number and variety of mobile devices, from smart phones to tablet computers, are in use. With over a decade of experience in pioneering paperless, mobile computing and wireless compliance capabilities in regulated laboratories, Accelrys will empower organizations to deploy purpose-built mobile applications in the lab from research to manufacturing, satisfying specific workflow requirements in accordance with Good Manufacturing Practice.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65931-accelrys-capture-drives-next-generation-mobility-in-the-laboratory
Construction is complete at A/D/O, a new 23,000 square-foot creative space, which opens to the public in Greenpoint, Brooklyn following the holiday season. At the core of A/D/O is its Design Academy, which aims to inspire pioneering work and be a forum for interdisciplinary debate. A/D/O will provide unique opportunities for professional development while inviting the broader public to explore design through a range of installations, exhibitions and events.
The Design Academy at A/D/O will offer an ambitious seasonal program geared towards design professionals, which stimulates relevant dialogue and new work through talks and workshops, special exhibitions and commissions and designer residencies. Its first program, entitled “Utopia vs. Dystopia: Designing Our Imagined Futures,” investigates the role design plays in a world of rapid change. Partnerships with design firms MOS Architects, OLIN, Stephen Burks Man Made and Turner-prize winning collective Assemble, as well as talks from Yves Behar and Alice Rawsthorn among others, are important components of this inaugural season, which will kick off with a three-day festival January 27-29, 2017.
To view the multimedia release go to:
http://www.multivu.com/players/English/7978851-a-d-o-opens-design-academy-greenpoint-brooklyn/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
